BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Subscribe To Our Newsletter & Stay Updated